CMPX
Compass Therapeutics Inc.
$
3.740
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.840
Open
3.720
VWAP
3.71
Vol
2.29M
Mkt Cap
641.68M
Low
3.630
Amount
8.49M
EV/EBITDA(TTM)
--
Total Shares
137.59M
EV
416.23M
EV/OCF(TTM)
--
P/S(TTM)
--
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
--
--
-0.139
+73.86%
--
--
-0.137
+24.79%
--
--
-0.134
+11.67%
Estimates Revision
The market is revising No Change the revenue expectations for Compass Therapeutics, Inc. (CMPX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 31.23%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+4.02%
In Past 3 Month
Stock Price
Go Up
+31.23%
In Past 3 Month
7 Analyst Rating
Wall Street analysts forecast CMPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPX is 12.29 USD with a low forecast of 7.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.740
Low
7.00
Averages
12.29
High
24.00
Current: 3.740
Low
7.00
Averages
12.29
High
24.00
Guggenheim
Michael Schmidt
Buy
maintain
$10 -> $12
2025-08-12
Reason
Guggenheim
Michael Schmidt
Price Target
$10 -> $12
2025-08-12
maintain
Buy
Reason
Guggenheim analyst Michael Schmidt raised the firm's price target on Compass Therapeutics to $12 from $10 and keeps a Buy rating on the shares. Q2 results included "a positive pipeline update and new clinical data," says the analyst, who notes that management is now officially guiding to announcing the final PFS and OS analysis of the ongoing COMPANION-002 Phase 2/3 trial of tovecimig in second-line and later biliary tract cancer in Q1 of 2026, versus Q4 of 2025 previously. The firm's raised target reflects the addition of highly probability-of-success-adjusted value for CTX-8371 and incrementally higher conviction on tovecimg, the analyst noted.
Raymond James
Sean McCutcheon
Outperform
initiated
$9
2025-07-01
Reason
Raymond James
Sean McCutcheon
Price Target
$9
2025-07-01
initiated
Outperform
Reason
Raymond James analyst Sean McCutcheon resumed coverage of Compass Therapeutics with an Outperform rating and $9 price target. Tovecimig has demonstrated superiority on response rate to its comparator arm in the Phase 3 COMPANION-002 study, notes the analyst, who believes it will hit statistical significance on progression-free survival with a U.S. approval in second-line biliary tract cancer during 2026. Should Tovecimig get approved, the firm thinks the launch of the drug will be "strong given the low bar" and lack of efficacy for standard chemotherapy regimens in the roughly 60% of second-line BTC patients without targetable genomic alterations, the analyst added.
Guggenheim
Buy
downgrade
$12 -> $10
2025-05-09
Reason
Guggenheim
Price Target
$12 -> $10
2025-05-09
downgrade
Buy
Reason
Guggenheim lowered the firm's price target on Compass Therapeutics to $10 from $12 and keeps a Buy rating on the shares. After the quarterly report, the firm updated its model to account for Q1 results and refined launch timing assumptions for tovecimig, the analyst tells investors.
Guggenheim
Michael Schmidt
Strong Buy
Reiterates
n/a
2025-04-22
Reason
Guggenheim
Michael Schmidt
Price Target
n/a
2025-04-22
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$32
2025-04-21
Reason
D. Boral Capital
Jason Kolbert
Price Target
$32
2025-04-21
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$24
2025-04-21
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$24
2025-04-21
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Compass Therapeutics Inc. (CMPX.O) is -6.84, compared to its 5-year average forward P/E of -6.13. For a more detailed relative valuation and DCF analysis to assess Compass Therapeutics Inc. 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.13
Current PE
-6.84
Overvalued PE
-3.53
Undervalued PE
-8.74
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.11
Current EV/EBITDA
-5.57
Overvalued EV/EBITDA
-0.56
Undervalued EV/EBITDA
-5.65
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
30.82
Current PS
3.74
Overvalued PS
140.94
Undervalued PS
-79.30
Financials
Annual
Quarterly
FY2025Q2
YoY :
-100.00%
0.00
Total Revenue
FY2025Q2
YoY :
+40.02%
-21.07M
Operating Profit
FY2025Q2
YoY :
+52.04%
-19.88M
Net Income after Tax
FY2025Q2
YoY :
+40.00%
-0.14
EPS - Diluted
FY2025Q2
YoY :
+10.02%
-11.83M
Free Cash Flow
FY2025Q2
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
11.4M
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
3
80.3K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
1.0M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
11.4M
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
3
80.3K
USD
Months
0-12
0
0.0
USD
Months
CMPX News & Events
Events Timeline
2025-08-13 (ET)
2025-08-13
06:15:31
Compass Therapeutics 33.3M share Spot Secondary priced at $3.00
2025-08-12 (ET)
2025-08-12
16:06:08
Compass Therapeutics announces common stock offering, no amount given
2025-08-11 (ET)
2025-08-11
07:05:49
Compass Therapeutics announces anticipated cash runway into 2027
Sign Up For More Events
Sign Up For More Events
News
1.0
09-10NewsfilterCompass Therapeutics, Inc. (CMPX) Shares Insights at Morgan Stanley's 23rd Annual Global Healthcare Conference Transcript
8.5
08-13NewsfilterCompass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
9.0
08-11SeekingAlphaCompass Therapeutics rises after pipeline updates
Sign Up For More News
People Also Watch
SAR
Saratoga Investment Corp
22.510
USD
+1.31%
TITN
Titan Machinery Inc
16.400
USD
+0.12%
NPCE
Neuropace Inc
9.940
USD
+0.81%
NECB
Northeast Community Bancorp Inc
19.640
USD
-2.00%
RRBI
Red River Bancshares Inc
66.060
USD
-2.58%
VLN
Valens Semiconductor Ltd
1.830
USD
+7.65%
QUAD
Quad/Graphics Inc
5.510
USD
+1.85%
RBB
RBB Bancorp
18.630
USD
-1.84%
RIGL
Rigel Pharmaceuticals Inc
31.580
USD
-0.13%
FAQ
What is Compass Therapeutics Inc. (CMPX) stock price today?
The current price of CMPX is 3.74 USD — it has increased 0.54 % in the last trading day.
What is Compass Therapeutics Inc. (CMPX)'s business?
What is the price predicton of CMPX Stock?
What is Compass Therapeutics Inc. (CMPX)'s revenue for the last quarter?
What is Compass Therapeutics Inc. (CMPX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Compass Therapeutics Inc. (CMPX)'s fundamentals?
How many employees does Compass Therapeutics Inc. (CMPX). have?